GLI1 and central nervous system cancer: Past studies have suggested that MGMT may serve as a transcriptional target of GLI1 by virtue of GLI-binding sites within its promoter region [25,77]; however, it was only until recently that evidence has shown that aberrant GLI1 activation regulates MGMT expression to confer chemoresistance in glioma.